CClinicalTrials.gg
CompletedNCT04515498CATCHUpdated May 30, 2023

A Prospective Clinical Study of the CloudCath System During In-home Peritoneal Dialysis

An observational study in Peritoneal Dialysis-associated Peritonitis, sponsored by CloudCath. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-30.

Sponsored by CloudCath · Observational

Study type
Observational
Model
Case-crossover
Time perspective
Prospective
Enrollment
243
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to determine if the CloudCath device can detect infections related to peritoneal dialysis (peritonitis) as fast or faster than the current standard methods used by patients and doctors to detect such infections.

Read the detailed description

This study will evaluate the safety and effectiveness of the CloudCath System to detect the onset of peritonitis as compared to standard of care.

Study Participants will connect the CloudCath System to their home peritoneal dialysis unit and the CloudCath System will analyze the effluent dialysis solution for changes associated with peritonitis. The notification capability of the CloudCath System will be deactivated for this study so that neither Study Participants nor Study Investigators will be aware of the device measurements.

Following enrollment, Study Participants will use the CloudCath System for 12 continuous months.

02

Conditions studied

  • Peritoneal Dialysis-associated Peritonitis

Browse trials for

03

In context

Peritonitis

185 studies on the registry are indexed under Peritonitis; 25 are open to participants now.

This study's enrollment of 243 is above the median of 127 across 59 observational studies indexed under Peritonitis.

Browse Peritonitis studies →

Lead sponsor

CloudCath is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients currently using home peritoneal dialysis.

Eligibility criteria

Key Inclusion Criteria:

  • currently using peritoneal dialysis
  • provides informed consent
  • willing to comply with the requirements of the study
  • has cellular data coverage at home

Key Exclusion Criteria:

  • active or history of cancer requiring chemotherapy within prior 6 months
  • signs or symptoms of an active infection within 14 days prior to enrollment
  • peritonitis diagnosis within 30 days prior to enrollment
  • participating in another investigational device or drug study that may potentially affect study results
  • other medical, social or psychological problems that, in the opinion of the investigator, exclude the study participant from the study
05

Study design

Observational model
Case-crossover
Time perspective
Prospective
Enrollment
243 participants (actual)
Patient registry
No

Groups and cohorts

  • CloudCath System

    Patients with End Stage Renal Disease (ESRD) currently using home peritoneal dialysis

    Device: CloudCath Monitoring System

Interventions

  • DeviceCloudCath Monitoring System

    The CloudCath Monitoring System will analyze effluent dialysate for changes associated with peritonitis.

06

What researchers measure

Primary outcomes

  1. Time of peritonitis detection (vs lab measures)

    The time peritonitis is detected by the CloudCath System, as compared to time of laboratory evidence of peritonitis

    Time frame: through 12 months

Secondary outcomes

  1. Time of peritonitis detection (vs clinical measures)

    The time peritonitis is detected by the CloudCath System, as compared to time of peritonitis detection by standard clinical means (ISPD guidelines)

    Time frame: through 12 months

  2. Sensitivity and specificity of the CloudCath System detection of peritonitis

    Analysis of sensitivity and specificity of CloudCath System detection of peritonitis, as compared to diagnostic laboratory testing

    Time frame: through 12 months

  3. Ability of study participants to use the CloudCath System as intended

    Device performance measure; ability to use as intended

    Time frame: through 12-months of study follow-up

Other outcomes

  1. Sensitivity and specificity of the CloudCath System detection of peritonitis and the resolution of peritonitis

    Analysis of sensitivity and specificity of the detection of peritonitis and the detection of the resolution of peritonitis, as compared to diagnostic laboratory testing

    Time frame: through 12 months

  2. Sensitivity and specificity of the CloudCath System detection of resolution of peritonitis

    Analysis of sensitivity and specificity of the resolution time of peritonitis

    Time frame: through 12 months

07

Study locations

1 site
  • CloudCath Investigational Site
    Lakewood, Colorado 80226, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04515498
Lead sponsor
CloudCath
Responsible party
Sponsor
First posted
Aug 17, 2020
Start date
Aug 19, 2020
Primary completion
Mar 31, 2023
Completion
Mar 31, 2023
Last update
May 30, 2023

Study contacts

Glenn Chertow, MD
study director · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion